Kite Pharma kitepharma.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of cancer immunotherapy products, with a primary focus on eACT designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide...Show all

Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of cancer immunotherapy products, with a primary focus on eACT designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with...Show all

Company (Acquired)

Phone: 650-574-3000

Fax:

2225 Colorado Avenue

Foster City, 94404
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Kite Pharma $212.8M Oct 3, 2017

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Kite Pharma Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 9 investors

Competitors

Company Status Description Investors

Bluebird Bio

Cambridge, Massachusetts, United States
IPO / Went publicBluebird Bio, formerly Genetix Pharmaceuticals, is developing gene therapies for severe genetic disorders. At the heart of bluebird bio's product creation efforts is its broadly applicable gene therapy platform for the development of treatments for diseases with few or no clinical options. The company's approach uses stem cells harvested from the patient's bone marrow into which a healthy version of the disease causing gene is inserted. After being grown in culture, those cells are given back to...Show allLogin to see details

Juno Therapeutics

Seattle, Washington, United States
AcquiredJuno Therapeutics (NASDAQ: JUNO) is a clinical-stage company that brings together three of the world's leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children's Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs. The CAR technology is designed t...Show allLogin to see details

Patents

Title Application Date Patent Date Status
(Patent / Application)
Methods of conditioning patients for t cell therapy May 27, 2016 Jan 02, 2018 Patent
Antigen binding molecules and methods of use thereof Sep 27, 2017 Application
Methods of making and using soluble mhc molecules Aug 11, 2017 Application
Methods of conditioning patients for t cell therapy Jul 13, 2017 Application
Antigen binding molecules and methods of use thereof Jul 11, 2017 Application
See all 9 patents